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Abstract
Measuring the severity and progression of facioscapulohumeral muscular dystrophy (FSHD) is particularly challenging because muscle
weakness progresses over long periods of time and can be sporadic. Biomarkers are essential for measuring disease burden and testing treatment
strategies.We utilized the sensitive, specific, high-throughput SomaLogic proteomics platform of 1129 proteins to identify proteins with levels that
correlate with FSHD severity in a cross-sectional study of two independent cohorts. We discovered biomarkers that correlate with clinical severity
and disease burden measured by magnetic resonance imaging. Sixty-eight proteins in the Rochester cohort (n = 48) and 51 proteins in the Seattle
cohort (n = 30) had significantly different levels in FSHD-affected individuals when compared with controls (p-value ≤ .005). A subset of these
varied by at least 1.5 fold and four biomarkers were significantly elevated in both cohorts. Levels of creatine kinase MM and MB isoforms,
carbonic anhydrase III, and troponin I type 2 reliably predicted the disease state and correlated with disease severity. Other novel biomarkers were
also discovered that may reveal mechanisms of disease pathology. Assessing the levels of these biomarkers during clinical trials may add
significance to other measures of quantifying disease progression or regression.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is an
adult onset, dominantly inherited, slowly progressive muscular
dystrophy with no treatment. Individuals are often diagnosed in
the second decade of life with symptoms of scapular winging,
foot drop, and facial muscle weakness [1]. These symptoms are
almost always progressive and spread to other muscle groups
resulting in debilitating weakness and reduced quality of
life [2]. The primary molecular event involves epigenetic
de-repression of a macrosatellite array of D4Z4 DNA repeats
on chromosome 4 resulting in the expression of the double
homeobox 4 (DUX4) gene in a small fraction of myonuclei
[3–7]. The DUX4 transcription factor is toxic to human [8] and
mouse [9,10] cells when overexpressed from viral vectors, and
cultured human myoblasts expressing endogenous DUX4 die
within 24 hours of DUX4 activation [11]. MRI studies of
FSHD-affected individuals show normal appearing muscle
adjacent to muscles with short-TI inversion recovery (STIR)
bright signal and muscles with fatty replacement of tissue
[12–15]. Although there is a predilection for certain muscle
groups, different muscles can be affected in different
individuals, or in different extremities of the same individual,
adding to the complexity of assessing disease burden. Several
therapeutic approaches are being developed [16,17] but tools
for assessing efficacy in the absence of animal models are
currently lagging the development of therapies [18].
Assessing therapeutic efficacy in a FSHD clinical trial is
challenging because the disease is highly variable and slowly
progressive, so strength measurements need to be taken in
large numbers of subjects over long time intervals to reveal
significant effects [2]. Biomarkers assessed in blood plasma or
serum that reflect disease pathology could provide a quick,
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objective, and quantitative assessment of disease severity,
allowing meaningful changes to be assessed in a time period
where functional changes may not yet be realized. Because all
muscles are exposed to the circulation, muscle-derived serum
proteins should reflect an average disease burden throughout
the body.
We used the SOMAscan assay, based on Slow Off-rate
Modified Aptamers, to assess the levels of 1129 target proteins.
The technology utilizes nucleic acid secondary structures to
recognize 3D epitopes on proteins with very high sensitivity and
specificity [19,20]. This platform has been used for the discovery
and validation of biomarkers in a number of diseases including
DMD [21],Alzheimer’s [22,23], non-small cell lung cancer [24],
and pulmonary tuberculosis [25]. We identified 4 proteins with
blood levels that independently correlated with the presence and
severity of disease in two separate FSHD cohorts and correlate
with MRI STIR bright signal in subjects from the Seattle cohort.
The serum levels of these biomarkers will be an important
parameter for validation in future longitudinal studies and should
allow quantification of disease severity in combination with MRI
or assessments of strength and movement.
2. Materials and methods
2.1. Standard protocol approvals, registrations, and patient
consents
Venipuncture was performed with informed consent using
documents and protocols approved by the Human Subjects
Independent Review Board (IRB) at the University of
Washington, Seattle, WA, and University of Rochester,
Rochester, NY. Subjects in the Seattle cohort also consented to
MRI studies as approved by the Seattle Children’s Hospital
IRB. Written informed consent was obtained from all subjects
participating in the study.
2.2. Study design
The Seattle cohort was composed of 18 FSHD-affected
individuals and 12 control subjects whom we obtained
demographic data, performed a brief physical exam, and
calculated clinical severity scores [26]. A blood sample was
obtained in an EDTA-containing tube (purple top) and plasma
was prepared from approximately 2 ml of uncoagulated whole
blood by centrifugation at 1500 × g for 10 min and freezing
samples at −80 °C. All samples were thawed once for
proteomic analysis. Additional sample was used to confirm a
FSHD diagnosis by pulse field gel electrophoresis (PFGE), and
Southern blots that were probed with the P13E11, “A”, and “B”
probes [27]. When a contracted D4Z4 fragment was not
observed, sequencing of SMCHD1 was performed and
mutations were confirmed to be causative by quantifying D4Z4
CpG methylation [28]. Subjects’ ages ranged from 20 to 79,
with 13 male and 5 female in the FSHD group and ages 21–72
with 6 male and 6 female in the control group.
Eleven of the same subjects with FSHD were recruited
for a study evaluating whole body MRI data. All MRI data
acquisition occurred at Seattle Children’s Hospital on a 3 T
Siemens Trio scanner running software VB17. Flexible array
coils were employed to collect data in the thigh, calf, upper
body (including shoulders, back, pectoral muscles) and
abdominal region. The following sequences were collected:
3-plane localizers, T1 (TE = 8.9 ms, TR = 510 ms, 320 × 224,
5 mm thick, 50 slices upper body/40 slices lower body), and
STIR (TE = 37 ms, TR = 4300, flip 150°, same resolution).
Likewise, physical exam, clinical severity scores and
demographic data were obtained from 24 FSHD-affected and
23 control subjects that comprise the Rochester cohort. Ages
ranged from 18 to 69, with 11 male and 13 female in the FSHD
group and 10 male and 13 female in the control group. A
diagnosis of FSHD was confirmed by PFGE. Serum was
prepared from clotted blood samples collected in vacu-tubes
without anti-coagulant (red top) by centrifugation at 1500 × g
for 10 min and freezing at −80 °C. All samples were thawed
once for proteomic analysis. The levels of 1129 proteins were
determined using the SomaLogic technology [20] by sending a
small frozen aliquot to SomaLogic Inc. for testing.
Subjects affected by diabetes, chronic obstructive
pulmonary disease, chronic heart failure, current malignancy,
previous treatment with chemotherapy or radiation, use of
corticosteroids for a period exceeding 2 weeks in the last 5
years, use of statins in the past year, wheel chair dependence, or
pregnancy were excluded.
2.3. SomaLogic proteomic methods
SomaLogic Inc. (Boulder, CO) performed analysis on serum
or plasma samples that had been stored at −80 °C or below and
had never been previously thawed. The SOMAmer-based
proteomic assay consists of equilibrium binding of fluorophore-
tagged SOMAmers and proteins in plasma in solution and
automated partitioning steps to capture only the SOMAmers that
are in complexes with their cognate proteins [20]. The assay
transforms the measurement of proteins into the measurement
of the corresponding SOMAmers via hybridization of the
SOMAmer DNA oligonucleotides to an array of antisense
probes using a hybridization gasket slide (Agilent Technologies,
Santa Clara, CA, USA). The liquid handling steps of the assay
(protein binding) are performed by a Biomek robot, and the
fluorescent signal generated in the hybridization step is captured.
Protein concentrations were reported in relative fluorescence
units (RFU).
2.4. Data analysis and statistical method
Data were analyzed using the R environment for statistical
computing. The Kolmogorov–Smirnov (KS) test [29] was used
for unpaired comparisons between FSHD and control subjects.
Correction for multiple comparisons was performed according
to the procedure of Benjamini and Hochberg [30] and adjusted
p-values (q-values) are shown in Tables 1 and 2. The list of
statistically significant biomarkers (p < .005) was limited to
those that had a 1.5 fold or greater change in concentration in
FSHD-affected subjects when compared with controls.
Unsupervised hierarchical clustering analysis was
performed using the Euclidean distance between the log2 of the
median expression ratio for a particular set of biomarkers and
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calculating a set of dissimilarities between samples using
Lance–Williams dissimilarity update formula according to the
method of Murtagh and Legendre.
Locally weighted scatterplot smoother (LOESS) curve
fitting line approximations were calculated using the R
environment and the ggplot2 package with the geom-smooth
function set to “loess”.
2.4.1. MRI scoring
One of the authors (MRF) blinded to subject phenotypes
assessed muscle change using a modified scale based on a
previously described rating scale for fat [31,32]. Briefly, 0:
normal; 1: scattered small areas of abnormality; 2: numerous
discrete areas of increased signal intensity, less than 30%
of the muscle volume; 3: numerous discrete areas with early
confluence, 30–60% volume; 4: >60% with patchy loss of
fascial structure; or 5: pronounced fatty replacement throughout
with complete fascial structure loss. In addition, the STIR+
intensity was rated according to the following categories: 0:
none; 1: minimal interfascicular edema; 2: minimal inter- and
intrafascicular edema; or 3: moderate inter- and intrafascicular
edema. Data were compiled for each subject and displayed as a
heat map to demonstrate the overall disease burden per subject.
3. Results
3.1. Selection and exclusion of subjects
Study subjects from the Seattle cohort consisted of members
of local support groups or FSHD research fund-raising activity
participants. Control individuals were identified randomly
or were asymptomatic and test-negative relatives of FSHD
subjects. Both control and FSHD-affected individuals who
were taking medications or had medical conditions that would
be predicted to alter muscle physiology were excluded (see the
section “Study design”). The Seattle cohort included sixteen
individuals with FSHD1 and two individuals with FSHD2.
Subjects grouped under the Rochester cohort were ascertained
similarly however serum was prepared from blood samples. All
FSHD-affected individuals in the Rochester cohort carried a
diagnosis of FSHD1 and the disease causing D4Z4 array
contraction.
3.2. Biomarkers with statistically significant differences in
serum or plasma concentration were identified in both the
Seattle and Rochester cohorts
The concentrations of 1129 different proteins were
determined for each subject in both cohorts. Because blood
samples were prepared slightly differently between cohorts, the
analysis could not be combined but independent analyses
allowed verification of significant findings within each cohort.
We found 51 proteins with plasma concentrations that differed
significantly between FSHD-affected and control groups in
the Seattle cohort (p value < .005). Sixty-eight proteins had
significantly different distributions of serum concentrations
comparing FSHD-affected and controls in the Rochester cohort
(p value < .005). Limiting these lists to proteins with at least a
1.5 fold difference between FSHD-subjects and controls
revealed 35 proteins in the Seattle cohort (Table 1) and 21
proteins in the Rochester cohort (Table 2), allowing us to focus
on biomarkers with maximum sensitivity and specificity.
3.3. Classification of biomarkers
Biomarkers found in both cohorts could be grouped into
several broad categories. Members of both lists included
skeletal muscle specific proteins found in the serum of subjects
with Duchenne muscular dystrophy (DMD) [21] and can be
characterized as proteins that leak into the blood as muscles
break down. These included creatine kinase isoforms MM and
MB, carbonic anhydrase types 3 and 13, Troponin I from fast
twitch skeletal muscle, and fatty acid binding protein (FABP3)
found both in heart and skeletal muscle.
Proteins involved in protein folding and maintenance of
aberrant cellular translation also represent a broad category
found in both lists.Members of this group include ubiquitin-fold
modifier 1 (UFM1), eukaryotic translation initiation factor 4
gamma 2 (IF4G2), vacuolar protein sorting-associated protein
VTA1 homolog (DRG-1), ribosomematuration protein (SBDS),
and heat shock 70 kDa protein 1A/1B (HSP70) and 60 kDa heat
shock protein, mitochondrial (HSPD1). With the exception of
HSP70, these proteins appear to be specific for FSHD pathology
as none were found to be significantly altered in a recently
published DMD study using the same technology [21].
Consistent with a recent report of novel pathways identified
in FSHD cells [11], proteins involved in cell adhesion, fusion,
and migration were also found to be significantly elevated in
FSHD-affected subjects. Members of this category include
2-phosphoinositide-dependent protein kinase 1 (PDPK1),
tyrosine-protein kinase (FER), and NSFL1 cofactor p47
(NSFL1C). Therefore this proteomics approach lends further
support to the importance of these pathways in FSHD
pathology [11].
Finally, proteins with a possible inflammatory role were
also present in both lists. These included complement 3b
(C3b), B-cell tyrosine-protein kinase (BTK), killer cell
immunoglobulin-like receptor 2DL4 (KIR2DL4), tumor
necrosis factor receptor superfamily member 11A
(TNFRSF11A), catalase (CAT), and matrix metalloproteinase 9
(MMP9). However, acute phase reactants that accompany both
acute and chronic inflammatory states were not among the
proteins found to be significantly elevated in FSHD-affected
individuals, suggesting that inflammation may not be a primary
component of the disease process.
3.4. Biomarker levels predict disease status
We noted several biomarkers that were present in both the
Seattle and Rochester lists (Tables 1 and 2). These included the
MM and MB isoforms of creatine kinase, carbonic anhydrase
III, and troponin I type 2. As expected, the variability was
narrow in control groups and larger in FSHD-affected groups
that had varying disease severities/burdens (Fig. 1). We focused
on the levels of these proteins to determine if they could predict
the disease state in subjects of either cohort. Utilizing the
technique of unsupervised hierarchical clustering, the samples
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were computationally arranged into blocks of similarity and the
log of the median expression ratio is indicated by color, with
blue being low and orange being high (Fig. 2). The disease
status is indicated by a solid bar on the left side of each map and
demonstrates that samples from FSHD-affected subjects group
together 93% of the time. Mis-groupings were limited to the
Rochester cohort where multiple individuals with very mild
disease symptoms (clinical severity score [CSS] = 0) were
included.
3.5. Plasma levels of four biomarkers correlate with
disease severity
Optimally, biomarkers should correlate with disease severity
so that their levels can be used to determine the efficacy of a
treatment during a clinical trial. We determined disease severity
using a previously published scoring criteria [26] and generated
a clinical severity score for each FSHD-affected subject (CSS,
Fig. 3A). Because the Seattle cohort contained a relatively even
distribution of subjects with CSS values ranging from 2 to 8,
the plasma concentration of each biomarker relative to the CSS
of the subjects within the Seattle cohort was plotted. Plasma
levels for all four markers correlated directly with CSS when
the CSS was ≤6 (Fig. 3A). Above a CSS of 6 biomarker levels
began to decline as might be expected when muscle volume has
decreased due to fatty replacement typically seen on the MRI of
subjects with advanced disease [14]. Carbonic anhydrase III
appears to have the largest dynamic range of the biomarkers
identified here and may be the most useful moving forward.
These data also provide information for the selection of
optimal clinical severities for entering clinical trials where
disease improvement or progression will be measured.
Additional metrics such as MRI and strength/movement
measurements are likely to add sensitivity to measuring disease
severity in the context of a clinical trial.
Table 1
Aptamer targets with significantly different plasma concentrations in the Seattle cohort.
Targeta Target protein description RFUb
(Control)
RFU
(FSHD)
FCc p-valued Adjusted
p-valuee
CA-III Carbonic anhydrase 3 2,241.9 8,530.0 3.8 2.31E−08 2.61E−05
CK-MB Creatine kinase M:Creatine kinase B 877.4 3,598.8 4.1 2.47E−06 1.40E−03
TNNI2 Troponin I, fast skeletal muscle 6,439.7 19,193.7 3.0 6.54E−06 2.46E−03
CK-MM Creatine kinase M-type 699.6 1,860.6 2.7 4.07E−05 7.66E−03
HSP 70 Heat shock 70 kDa protein 1A/1B 7,168.3 10,794.2 1.5 4.49E−04 2.67E−02
KI2L4 Killer cell immunoglobulin-like receptor 2DL4 1,110.1 2,113.4 1.9 8.89E−04 4.02E−02
MMP-9 Matrix metalloproteinase-9 18,897.5 35,708.6 1.9 1.74E−03 4.90E−02
FABP Fatty acid-binding protein 1,553.5 4,202.8 2.7 1.74E−03 4.90E−02
TNFRSF11A Tumor necrosis factor receptor superfamily member 11A 1,036.6 2,840.1 2.7 3.13E−03 7.35E−02
CAT Catalase 12,738.6 24,318.3 1.9 3.13E−03 7.35E−02
METAP1 Methionine aminopeptidase 1 4,173.2 1,398.7 −3.0 4.07E−05 7.66E−03
BTK Tyrosine-protein kinase BTK 7,640.7 2,621.1 −2.9 1.01E−04 1.63E−02
PTPN6 Tyrosine-protein phosphatase non-receptor 6 3,872.8 2,579.8 −1.5 2.11E−04 1.84E−02
CSK Tyrosine-protein kinase CSK 6,546.6 2,537.4 −2.6 2.11E−04 1.84E−02
PKCB Protein kinase C beta type (variant beta-II) 8,577.8 3,186.4 −2.7 2.11E−04 1.84E−02
PPIF Peptidyl-prolyl cis-trans isomerase F, mitochond. 18,723.6 5,525.1 −3.4 2.11E−04 1.84E−02
PRKCA Protein kinase C alpha type 28,408.3 7,684.1 −3.7 2.11E−04 1.84E−02
PRKACA cAMP-dependent protein kinase cat. subunit α 3,604.3 952.4 −3.8 2.11E−04 1.84E−02
AKT1 Protein kinase B alpha/beta/gamma 3,155.0 1,787.9 −1.8 3.29E−04 2.66E−02
PDIA3 Protein disulfide-isomerase A3 8,103.7 5,002.3 −1.6 4.49E−04 2.67E−02
ITGA2B Integrin alpha-IIb: beta-3 24,449.8 8,392.3 −2.9 4.49E−04 2.67E−02
CAXIII Carbonic anhydrase 13 2,880.9 859.8 −3.4 4.49E−04 2.67E−02
PRKCQ Protein kinase C theta type 3,472.1 1,976.9 −1.8 8.89E−04 4.02E−02
DBNL Drebrin-like protein 2,187.7 1,507.2 −1.5 1.74E−03 4.90E−02
YWHAB 14-3-3 protein family 6,280.4 3,031.9 −2.0 1.74E−03 4.90E−02
PPID Peptidyl-prolyl cis-trans isomerase D 4,003.2 1,753.3 −2.3 1.74E−03 4.90E−02
PDE5A cGMP-specific 3′,5′-cyclic phosphodiesterase 19,191.8 6,694.4 −2.9 1.74E−03 4.90E−02
HSPD1 60 kDa heat shock protein, mitochondrial 23,223.0 7,291.5 −3.2 1.74E−03 4.90E−02
SRC Proto-oncogene tyrosine-protein kinase Src 34,491.7 8,094.9 −4.3 1.74E−03 4.90E−02
EIF4G2 Eukaryotic translation initiation factor 4 gamma 2 2,692.3 468.6 −5.8 1.74E−03 4.90E−02
HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 4,863.7 1,714.4 −2.8 3.13E−03 7.35E−02
PDPK1 3-phosphoinositide-dependent protein kinase 1 2,110.9 525.3 −4.0 3.13E−03 7.35E−02
PPP3CA Calcineurin 1,925.5 1,002.9 −1.9 3.32E−03 7.36E−02
LYN Tyrosine-protein kinase Lyn 8,987.8 3,100.4 −2.9 3.32E−03 7.36E−02
FER Tyrosine-protein kinase Fer 1,285.4 207.9 −6.2 3.32E−03 7.36E−02
a Significant targets were defined as those having a FC ≥ 1.5 and p-value ≤ .005.
b RFU = Relative fluorescence units.
c FC = Fold change.
d p-values are from the D-statistic generated with the Kruskal–Wallis test.
e False discovery rate was determined by adjusting p-values for multiple testing using the formula of Benjamini and Hochberg.
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3.6. Biomarker levels correlate with STIR bright muscle
involvement determined by whole body MRI
Whole body MR imaging was performed on 11 of the 18
FSHD-affected subjects from the Seattle cohort. A radiologist
scored the intensity of the signal produced by T1 weighted
images (Fig. 3B, left panel) and short-T1 inversion recovery
(STIR, Fig. 3B, right panel) for each of 50 muscles (right and
left sides). The STIR scores were totaled for each subject to
produce a score that loosely approximates active disease
Table 2
Aptamer targets with significantly different serum concentrations in the Rochester cohort.
Targeta Target protein description Mean RFUb
(Control)
Mean RFU
(FSHD)
FCc p-valued Adjusted
p-valuee
CK-MB Creatine kinase M:Creatine kinase B heterodimer 2,153.3 4,867.5 2.3 2.65E−05 5.99E−03
CA- III Carbonic anhydrase 3 2,687.2 6,040.8 2.2 3.21E−05 6.05E−03
TCTP Translationally-controlled tumor protein 3,984.9 6,907.3 1.7 8.12E−05 1.02E−02
CK-MM Creatine kinase M-type 1,108.8 2,006.3 1.8 2.84E−04 1.69E−02
CSK Tyrosine-protein kinase CSK 1,018.7 1,612.0 1.6 2.37E−04 1.69E−02
PDPK1 3-phosphoinositide-dependent protein kinase 1 776.5 1,478.3 1.9 2.37E−04 1.69E−02
NUDCD3 NudC domain-containing protein 3 550.5 2,059.8 3.7 6.76E−04 3.02E−02
FER Tyrosine-protein kinase Fer 325.1 653.4 2.0 8.29E−04 3.02E−02
NSF1C NSFL1 cofactor p47 1,043.7 1,952.4 1.9 8.29E−04 3.02E−02
DUS3 Dual specificity protein phosphatase 3 1,000.4 2,009.8 2.0 7.46E−04 3.02E−02
UFM1 Ubiquitin-fold modifier 1 3,708.3 5,593.3 1.5 6.62E−04 3.02E−02
SHC1 SHC-transforming protein 1 8,151.0 15,477.8 1.9 8.29E−04 3.02E−02
IF4G2 Eukaryotic translation initiation factor 4 gamma 2 1,087.2 1,737.5 1.6 9.88E−04 3.38E−02
C3b Complement C3b 4,002.6 6,241.6 1.6 1.97E−03 5.30E−02
DRG-1 Vacuolar sorting-associated protein VTA1 homolog 14,957.0 28,488.9 1.9 2.36E−03 5.33E−02
GPVI Platelet glycoprotein VI 10,462.9 16,710.3 1.6 2.36E−03 5.33E−02
SBDS Ribosome maturation protein SBDS 1,796.2 2,894.3 1.6 2.03E−03 5.33E−02
PSMA Glutamate carboxypeptidase 2 2,917.7 4,791.0 1.6 2.55E−03 5.48E−02
TNNI2 Troponin I, fast skeletal muscle 8,282.0 15,461.1 1.9 3.02E−03 5.48E−02
CA-XIII Carbonic anhydrase 13 3,102.6 7,303.8 2.4 2.63E−03 5.48E−02
BTK Tyrosine-protein kinase BTK 1,483.7 3,241.0 2.2 3.02E−03 5.48E−02
a Significant targets were defined as those having a FC ≥ 1.5 and p-value ≤ .005.
b RFU = Relative fluorescence units.
c FC = Fold change.
d p-values are from the D-statistic generated with the Kruskal–Wallis test.
e False discovery rate was determined by adjusting p-values for multiple testing using the formula of Benjamini and Hochberg.
Fig. 1. Biomarker concentrations in controls and FSHD-affected subjects from the Rochester and Seattle cohorts. Box plots (25th–75th percentile) and whiskers
(Tukey’s method) showing comparisons of plasma concentrations for each of four biomarkers in control and FSHD-affected subjects. The black bar indicates median
value, outliers (more or less than 3/2 times the upper and lower quartiles) are shown as single dots. (A) Rochester cohort with control group in light blue and FSHD
group in dark blue. (B) Seattle cohort with control group in light red and FSHD group in dark red.
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burden. Subjects were ranked by disease severity using either
biomarker levels or the STIR score, and the rank score
determined by plasma biomarker concentrations was plotted
versus the rank score determined by STIR bright quantification.
Despite the lack of radiographic information on muscle
volume, a positive correlation between these ranks was
observed that approached significance (rho = 0.354, p = 0.14).
4. Discussion
FSHD is caused by epigenetic and genetic elements that are
unique to the primate lineage [33], a feature that makes
development of animal models challenging [34]. Therefore,
it may be necessary to test treatments in humans after
toxicology studies have been completed in animals. Because
FSHD is slowly progressive, conventional testing of muscle
strength and function to measure disease progression in the
context of a treatment requires large numbers of subjects with
measurements taken over long periods of time [2]. Given the
limited number of individuals able to participate in clinical
trials, and the length of time that may be necessary to show a
significant effect, having sensitive acutely-changing biomarkers
may allow quick assessment of a number of therapeutic
approaches. All skeletal muscles are exposed to the circulation
so biomarker levels may also reflect overall disease burden in
ways not possible by limited examination, biopsy, or imaging
techniques. We used an emerging technology to detect novel
disease biomarkers in the serum of people affected by FSHD
and identified several that correlate with the disease state,
severity, and MR imaging. These biomarkers may be more
responsive to disease progression than conventional clinical
outcome measures and therefore may be crucial for the efficient
conduct of future clinical trials.
Unlike the muscle destruction seen in DMD, the smoldering
prolonged muscle destruction typical of FSHD-affected
muscles necessitates precise measurement of biomarker
concentrations so that subtle changes can be detected. The
Fig. 2. Heat maps of Rochester and Seattle cohorts showing unsupervised clustering. Each map shows the relationship of the Euclidean distances between the log2
of the median expression ratio for each biomarker. Log2 median expression ratios are assigned a color based on the value and the color bin’s are plotted in the spectral
graph above each map (x axis). The line drawn over the spectrum shows the frequency of samples with each particular color or bin (y axis). A dendrogram drawn
to the left of each map shows relative similarities between samples. The color coded column labeled CSS shows the disease status (orange = FSHD and
green = Control) with the clinical severity score of the FSHD subject adjacent to the respective sample row.
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Fig. 3. Biomarker concentrations correlate with clinical severity of FSHD. (A) Individual plots of the plasma concentration of each biomarker (relative fluorescence
on the y axis) relative to clinical severity score (x axis) from the Seattle cohort. A LOESS polynomial regression was performed to draw a best fit line and the region
in dark gray indicates the 95% confidence interval of the mean. (B) Heat maps showing relative amounts of fat infiltration (left) and STIR bright signal (right) from
the right and left sides of 50 different muscles in 11 subjects from the Seattle cohort. The T1 weighted signal (fat bright) was scored on a scale of 0–5, with 0 being
normal and 5 being complete fatty replacement of the indicated muscle. STIR bright signal was scored from 0 (no signal) to 3 (maximum brightness). White boxes
indicate that the radiologist was unable to assign a score to that muscle. The active disease burden was quantified by summing the left and right side STIR signal
scores for each subject and is shown below the STIR bright heat map.
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SomaLogic technology used here has high specificity and
sensitivity over 4 logs providing a large dynamic range for
assessment [20]. Importantly the dynamic range exceeds that of
traditional methods of measurement and suggests that
biomarkers that may have traditionally seemed too variable for
disease assessment may be worth re-evaluating. Several studies
have now shown the variation of markers such as CK in large
numbers of control and dystrophy-affected subjects and the
trends appear to be more reliable than previously thought
[21,35,36]. In addition, following biomarker levels in a single
individual over time establishes a subject-specific baseline and
thus allows one to determine directional variation from that line
regardless of the absolute level.
We saw a weak correlation of the number of STIR (+)
muscles determined by MRI with biomarker levels. The weak
correlation was not surprising given that not all muscles
could be scored (including facial muscles that are significantly
affected in FSHD), quantification of MRI signals is
subjective, MRI changes may not be seen for some damaged
muscle states, and MRI scoring as performed here did not
take into account the volume of the affected muscle (so the
quadriceps contributed to the score equally to the tibialis
anterior).
In addition to allowing measurement of disease burden,
biomarker discovery provides insight into disease pathology.
Although not particularly surprising, the pattern of biomarker
levels as they are plotted against disease severity suggests a
decrease inmuscle tissue at the severe end of the clinical severity
spectrum. Decreased muscle tissue with fat replacement is seen
when severely affected individuals are imaged by MRI and
assessment of these biomarkers allows quantification of MRI
findings. Also, a unique group of biomarkers (proteins involved
in protein folding and translational processing) were discovered
that have not been observed in a larger DMD study and lend
further support to the ideas that cell migration [11] and
translation of transcripts normally degraded by nonsense
mediated decay (NMD) [37] or mis-spliced transcripts [11] are
important features of FSHD molecular pathology.
Likely multiple modalities of disease assessment will be
necessary to evaluate changes in clinical presentation over the
course of a clinical trial. Serum biomarkers, MRI, facial
movement, muscle strength, and dynamic assessments of gait
and activity can be combined to increase the power of
assessment of disease progression. It will be important to
follow the levels of biomarkers over time to measure disease
progression in the same individuals and to correlate plasma
concentrations with other sensitive measures of disease burden
such as MRI imaging of muscle pathology.
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